SQZ Biotechnologies Co

SQZ Biotechnologies Co (SQZ) priced its initial public offering on Oct 30, 2020 at $16.00 per share, within its $16.00–$18.00 range, raising $70.6M, and listed on NYSE. At the IPO price its market capitalization was about $383.6M. BofA Securities was lead-left underwriter, joined by Evercore ISI, Stifel and BTIG. Latham & Watkins advised the company and Goodwin Procter advised the underwriters.

SQZ Biotechnologies Co is a clinical-stage biotechnology company developing cell therapies for cancer, infectious diseases and other serious conditions. Its Cell Squeeze technology passes cells through a microfluidic chip to temporarily open the membrane and load material, with production time under 24 hours.

Status

IPO

Ticker

SQZ

Exchange

NYSE

Priced

Oct 30, 2020

IPO price

$16.00

Price range

$16.00–$18.00

Raised

$70.6M

Market cap at IPO price

$383.6M

First filed

Oct 9, 2020

Underwriters

BofA Securities, Evercore ISI, Stifel and BTIG

Company counsel

Latham & Watkins

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.